REDUCTION OF ST SEGMENT ELEVATION IN DIABETIC PATIENTS WITH MYOCARDIAL INFARCTION AFTER THROMBOLYTIC THERAPY
Abstract
Background: Acute coronary artery disease (CAD) is one of the main cause of death in today’s world. Myocardial infarction (MI) tends to be more common among diabetic patients. One of the most effective and used (in our settings) methods of resolution of MI is administration of streptokinase (SK). This study was conducted with the aim to determine the efficacy of thrombolytic therapy in reduction of ST segment elevation in acute MI patients presenting with diabetes. Methods: A descriptive case series with selection of 130 patients through non-probability purposive sampling was conducted at the Medical Departments of Services Hospital Lahore. The study was completed in 6 Months. Patients 18–80 years of age having either gender diagnosed with confirmed acute myocardial infarction were included in this study. All patients were then injected with streptokinase 1.5 mu. Pre and Post SK ECGs were done and ST segment elevation measured also measuring reduction of ST segment. Results: The mean age of the patients was noted as 54.42±8.80 years. There were 62.31% males. Mean reduction in ST-segment elevation of the patients was noted as 58.53±26.01. The efficacy was achieved in 47.7% patients. Conclusion: It is concluded that SK can be effective in almost half of diabetic patients with myocardial infarction.Keywords: Coronary Artery Disease; Myocardial Infarction; Streptokinase; ST segment reductionReferences
Abbas S, Kitchlew A, Abbas S. Disease burden of Ischemic Heart Disease in Pakistan and its risk factors. Ann Pak Inst Med Sci. 2009;5:145-50.
Bashore TM, Granger CB, Patrick H, Patel RM. Current Medical Diagnosis and Treatment. 51st ed. USA: The McGraw-Hill Companies. Heart diseases: McPhee SJ, Papadakis MA (eds) 2012;52(23):e143-e263.
AHA. Cardiovascular disease and diabetes. 2012 [cited 2014]; Available from: http://www/heart.org/HEARTORG/Conditions/Diabetets/WhyDiabetesMatters/Cardiovascular-Disease-Diabetes_UCM_313865_Article.
jama.2007;298(7):765-775.doi:10.1001/jama.298.7.765
Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135-43.
Masoom M, Samadi S, Sheikvatan M. Thrombolytic effects of SK Infusion assessed by ST segment resolution between diabetic and non-diabetic myocardial infarction patients. Cardiol J. 2012;19(2):168-73.
Hafizullah M. Diabetes-A cardiovascualr disease. Pak Heart J. 2014;46(4).
Uddin MF, Hoque AF. Impact of Diabetic Mellitus on the Effect of Streptokinase in Acute Myocardial Infarction Patients. Med Today. 2013;24(1):16-9.
Gemmill J, Hogg K, Dunn F, Rae A, Hillis W. Pre-dosing antibody levels and efficacy of thrombolytic drugs containing streptokinase. Br Heart J. 1994;72(3):222-5.1. Abbas S, Kitchlew AR, Abbas S. Disease burden of Ischemic Heart Disease in Pakistan and its risk factors. Ann Pak Inst Med Sci 2009;5(3):145–50.
Bashore TM, Granger CB, Patrick H, Patel RM. Heart diseases. In: McPhee SJ, Papadakis MA, editors. Current medical diagnosis & treatment 2012. 51st ed. New York: McGraw-Hill Medical; 2011.p.143–263.
American Heat Association. Cardiovascular disease and diabetes 2012. [Internet]. [cited 2014 Nov 10]. Available from: http://www/heart.org/HEARTORG/Conditions/Diabetets/WhyDiabetesMatters/Cardiovascular-Disease-Diabetes_UCM_313865_Article
Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, et al. Diabetes and Mortality Following Acute Coronary Syndromes. JAMA 2007;298(7):765–75.
Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105(9):1135–43.
Masoom M, Samadi S, Sheikvatan M. Thrombolytic effects of strptokinase Infusion assessed by ST segment resolution between diabetic and non-diabetic myocardial infarction patients. Cardiol J 2012;19(2):168–73.
Hafizullah M. Diabetes-A cardiovascualr disease. Pak Heart J 2013;46(4):720–24.
Uddin MF, Hoque AF. Impact of Diabetic Mellitus on the Effect of Streptokinase in Acute Myocardial Infarction Patients. Med Today 2013;24(1):16–9.
Gemmill JD, Hogg KJ, Dunn FG, Rae AP, Hillis WS. Pre-dosing antibody levels and efficacy of thrombolytic drugs containing streptokinase. Br Heart J 1994;72(3):222–5.
Published
Issue
Section
License
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
